Lateral Flow Assays Market Report 2035: Industry Size to Hit USD 22.78 Billion by 2035 | SNS Insider

Global demand for rapid diagnostics is accelerating, with the U.S. market forecast to reach $7.10B by 2035 and Europe $6.36B. Growth is supported by expanding home testing, broader clinical diagnostics, adoption of multiplex detection assays, and increased use of digital readers.

Analysis

The investable change here is not raw test demand; it is where the margin pools migrate. As testing moves from centralized labs toward at-home, multiplex, and reader-based workflows, value should accrue to companies that own assay content, consumables, and installed-base software, while commoditized volume labs face mix pressure and lower pricing power. That is mildly constructive for platform diagnostics and pharmacy-channel distribution, but it is a headwind for DGX/LH-style businesses that depend on low-acuity routine testing and specimen throughput.

Near term, this is mostly a narrative trade unless there is visible reimbursement or FDA-cleared product cadence. Over the next 1-3 months, the key checks are reader placements, repeat consumables pull-through, and whether consumer adoption is actually recurring versus one-off seasonal demand; over 6-18 months, payer coverage and panel breadth determine whether the TAM becomes earnings or just top-line noise. The thesis fails if adoption stalls after launch, if gross-to-net rises, or if labs recapture share through lower-priced bundled offerings.

The contrarian miss is that the market may be overestimating how much of a 2035 forecast converts into present value. Long-dated addressable markets usually support higher multiples only when near-term operating leverage is visible; otherwise, the better expression is relative value, not outright beta. I would also watch CVS and other retail channels as second-order beneficiaries of traffic and attachment sales, but the economics likely remain with manufacturers, not retailers.

Key Decisions for Investors

• Prefer a relative-value long ABT / short DGX or LH pair over 3-6 months; the setup is a mix-and-margin trade, not a pure growth bet. Target 10-15% relative outperformance; cut if lab volume or pricing improves materially in the next two earnings prints.
• Do not chase the broad diagnostics theme outright until there is evidence of recurring consumables pull-through or reimbursement support. The forecast is too long-dated to justify paying up on headline TAM alone.
• Watch QDEL as a high-beta expression of home-testing adoption, but only as a conditional alert: initiate only if channel checks show sustained reorder behavior and stable reader placement. Otherwise the risk/reward remains poor because one-off consumer demand can reverse quickly.
• If the group sells off on no-news, use any 2-3% pullback in ABT to add via call spreads rather than stock. The payoff is best if the market re-rates platform diagnostics before the next respiratory season; invalidation is slowing assay/menu growth or margin compression.